In a filing, Voyager Therapeutics Inc revealed its Chief Medical Officer Ferguson Toby unloaded Company’s shares for reported $34595.0 on Apr 02 ’25. In the deal valued at $3.43 per share,10,086 shares were sold. As a result of this transaction, Ferguson Toby now holds 157,914 shares worth roughly $0.52 million.
Then, Sandrock Alfred sold 10,885 shares, generating $37,336 in total proceeds. Upon selling the shares at $3.43, the President and CEO now owns 430,931 shares.
Before that, Sandrock Alfred bought 10,885 shares. Voyager Therapeutics Inc shares valued at $37,369 were divested by the Officer at a price of $3.43 per share.
Cantor Fitzgerald initiated its Voyager Therapeutics Inc [VYGR] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Leerink Partners started covering the stock on October 16, 2024. It rated VYGR as “an Outperform”.
Price Performance Review of VYGR
On Tuesday, Voyager Therapeutics Inc [NASDAQ:VYGR] saw its stock fall -0.30% to $3.28. Over the last five days, the stock has gained 16.31%. Voyager Therapeutics Inc shares have fallen nearly -42.15% since the year began. Nevertheless, the stocks have fallen -59.71% over the past one year. While a 52-week high of $9.55 was reached on 01/07/25, a 52-week low of $2.64 was recorded on 05/30/25. SMA at 50 days reached $3.29, while 200 days put it at $5.19.
Levels Of Support And Resistance For VYGR Stock
The 24-hour chart illustrates a support level at 3.19, which if violated will result in even more drops to 3.11. On the upside, there is a resistance level at 3.40. A further resistance level may holdings at 3.52. The Relative Strength Index (RSI) on the 14-day chart is 52.61, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 41.47%. Stochastics %K at 42.94% indicates the stock is a holding.
The most recent change occurred on March 26, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $22 price target.
